Vaccine Deal from Bayer and CureVac NV

A vaccine deal came from Bayer and CureVac NV. Bayer AG will cooperate for the international approval and distribution of the coronavirus vaccine developed by the German biotech company CureVac NV. In a joint statement made by Bayer and CureVac, it was stated that the developed coronavirus vaccine is planned to obtain legal permission from Europe and worldwide and to produce several hundred million doses. CureVac Chief Executive Officer Franz-Werner Haas previously said he was looking for a major pharmaceutical partner. In the statement Haas said, “After obtaining the necessary approvals, we now have another strong partner with us to deliver the vaccine to those in need.” It was stated that the vaccine candidate developed by CureVac, used mRNA technology which is used by Moderna Inc. and BioNTech SE-Pfizer Inc. and was in an advanced clinical trial process. Both vaccines developed by Moderna and BioNTech-Pfizer with mRNA technology, showed high efficiency and became one of the first vaccines to be approved by the European Union and other countries.